NCT00005066View on ClinicalTrials.gov

O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

September 30, 2001

Study Completion Date

October 31, 2002

Conditions
Sarcoma
Interventions
DRUG

O6-benzylguanine

DRUG

carmustine

Trial Locations (10)

46617

Michiana Hematology/Oncology P.C., South Bend

60068

Division of Hematology/Oncology, Park Ridge

60201

Evanston Northwestern Health Care, Evanston

60612

University of Illinois at Chicago, Chicago

60637

University of Chicago Cancer Research Center, Chicago

60640

Louis A. Weiss Memorial Hospital, Chicago

61602

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

62526

Cancer Care Specialists of Central Illinois, S.C., Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

46885-5099

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT00005066 - O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter